Arovella Therapeutics (ASX: ALA)

Currency in AUD

Last close As at 06/02/2023

AUD0.02

−0.01 (−33.33%)

Market capitalisation

AUD17m

Arovella Therapeutics is a biotech company focused on oncology through its iNKT cell therapy platform. In 2021 it acquired a CAR-iNKT programme for haematological malignancies and a DKK1 antibody that has potential in multiple myeloma and solid tumours. In October 2022 it announced that it would cease further development work on its legacy platform, OroMist.

ALA is targeting very large markets including insomnia (through ZolpiMist) and various cancers (through the CAR-iNKT programme and anagrelide).

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Michael Baker

    CEO and Managing Director

Balance Sheet

Forecast net debt (A$m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 0.0 (21.9) (39.0)
Relative (5.5) (29.3) (41.2)
52 week high/low A$0.0/A$0.0

Financials

Arovella Therapeutics is focused on the immunoncology space (in particular cell therapies) following the in-licensing in CY21 of two chimeric antigen receptor (CAR) based immunotherapies (both in preclinical stage). The first was an invariant natural killer T (iNKT) cell therapy platform in-licensed from Imperial College London in July 2021. The platform can be combined with CARs to target blood cancers, with a potential of being an allogeneic ‘off-the-shelf’ therapy. This was followed by the in-licensing of a novel monoclonal antibody targeting a Dickkopf-1 (DKK1) peptide from MD Anderson Cancer Center in December 2021. Arovella plans to combine the DKK1 targeting technology with the iNKT cell therapy platform in future. In September 2022, Arovella signed a strategic collaboration with Imugene to investigate the combined potential of the company’s lead CAR19-iNKT programme ALA-101 with Imugene’s onCARlytics (CF33-CD19) platform in treating solid tumours. Following this the company has decided to cease all R&D activities related to its legacy OroMist platform.

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (c) P/E (x) P/CF (x)
2021A 0.3 (3.1) (3.4) (1.15) N/A N/A
2022A 0.3 (7.0) (7.4) (1.42) N/A N/A
2023E N/A N/A N/A N/A N/A N/A
2024E N/A N/A N/A N/A N/A N/A

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free